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Introduction {#jdi12361-sec-0005}
============

Diabetic peripheral neuropathy is a nerve disorder complication of diabetes, affecting up to 47% of patients with diabetes[1](#jdi12361-bib-0001){ref-type="ref"}. The socioeconomic burden of diabetic complications is increasing rapidly in Asia[2](#jdi12361-bib-0002){ref-type="ref"}, and Japan is expected to remain one of the top 10 countries worldwide for diabetes prevalence in 2030[3](#jdi12361-bib-0003){ref-type="ref"}. Up to 22% of patients with diabetes experience chronic diabetic neuropathic pain (DNP)[4](#jdi12361-bib-0004){ref-type="ref"}, [5](#jdi12361-bib-0005){ref-type="ref"}. Symptoms of DNP include aching, burning, tingling and stabbing sensations[6](#jdi12361-bib-0006){ref-type="ref"}, and the condition is associated with decreased quality of life, sleep impairment, anxiety and depression[7](#jdi12361-bib-0007){ref-type="ref"}, [8](#jdi12361-bib-0008){ref-type="ref"}, [9](#jdi12361-bib-0009){ref-type="ref"}. Pharmacological treatments for DNP focus on pain relief, and include tricyclic antidepressants, anticonvulsants and serotonin noradrenaline reuptake inhibitors[10](#jdi12361-bib-0010){ref-type="ref"}, [11](#jdi12361-bib-0011){ref-type="ref"}. However, the efficacy of some treatments can be compromised by adverse events, including cardiovascular complications, weight gain and hyperglycemia[12](#jdi12361-bib-0012){ref-type="ref"}, [13](#jdi12361-bib-0013){ref-type="ref"}, [14](#jdi12361-bib-0014){ref-type="ref"}.

Duloxetine, which selectively inhibits serotonin and noradrenaline reuptake from the central nervous system with relatively balanced affinity[15](#jdi12361-bib-0015){ref-type="ref"}, has shown promising efficacy and safety for the treatment of DNP[16](#jdi12361-bib-0016){ref-type="ref"}, [17](#jdi12361-bib-0017){ref-type="ref"}, [18](#jdi12361-bib-0018){ref-type="ref"}, [19](#jdi12361-bib-0019){ref-type="ref"}, [20](#jdi12361-bib-0020){ref-type="ref"}, [21](#jdi12361-bib-0021){ref-type="ref"}, [22](#jdi12361-bib-0022){ref-type="ref"}. Duloxetine provides relief from DNP[16](#jdi12361-bib-0016){ref-type="ref"}, [17](#jdi12361-bib-0017){ref-type="ref"}, [19](#jdi12361-bib-0019){ref-type="ref"}, [23](#jdi12361-bib-0023){ref-type="ref"}, and has been associated with improvements in quality of life[19](#jdi12361-bib-0019){ref-type="ref"} and cognitive function[16](#jdi12361-bib-0016){ref-type="ref"}. Both short‐ and long‐term duloxetine treatment have been reported as having generally favorable safety profiles[17](#jdi12361-bib-0017){ref-type="ref"}, [18](#jdi12361-bib-0018){ref-type="ref"}, [21](#jdi12361-bib-0021){ref-type="ref"}, [23](#jdi12361-bib-0023){ref-type="ref"}, [24](#jdi12361-bib-0024){ref-type="ref"}. However, duloxetine treatment has been associated with changes in bodyweight, fasting blood glucose and glycosylated hemoglobin (HbA1c) levels, particularly after longer treatment[19](#jdi12361-bib-0019){ref-type="ref"}, [25](#jdi12361-bib-0025){ref-type="ref"}.

In Japan, duloxetine was approved for the treatment of DNP in February 2012, and was shown as being superior to placebo in a 12‐week, double‐blind, randomized, placebo‐controlled study of DNP in Japanese patients[22](#jdi12361-bib-0022){ref-type="ref"}. The primary efficacy outcome of 24‐h average pain score was significantly improved for patients treated with duloxetine (40 or 60 mg/day) compared with placebo, and no clinically important safety concerns were noted[22](#jdi12361-bib-0022){ref-type="ref"}. To examine long‐term duloxetine treatment in Japanese adults with DNP, we carried out a randomized, 52‐week, open‐label extension of that study. This is the first publication to present efficacy and safety (primary outcome) results from a long‐term study carried out in Asia with entirely Japanese patients.

Materials and Methods {#jdi12361-sec-0006}
=====================

Study Design {#jdi12361-sec-0007}
------------

This was a randomized, 52‐week, open‐label study (ClinicalTrials.gov no. NCT00641719) carried out at 71 sites from March 2008 to March 2010, which recruited participants who completed a 12‐week, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, phase 3 study (NCT005‐52175)[22](#jdi12361-bib-0022){ref-type="ref"}. Both studies were approved by the ethical review board at each site, and carried out in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and all applicable laws and regulations. All participants provided written informed consent before any study‐related procedures.

Study Population {#jdi12361-sec-0008}
----------------

Participants who completed the double‐blind study and whose most recent HbA1c value was ≤9.4% were invited to enrol in the long‐term study. As described previously[22](#jdi12361-bib-0022){ref-type="ref"}, the double‐blind study included Japanese adults with sustained pain for at least 6 months as a result of polyneuropathy caused by diabetes. All participants met the Diabetic Neuropathy Study Group of Japan criteria for diabetic peripheral neuropathy[26](#jdi12361-bib-0026){ref-type="ref"}. Individuals were excluded if they had a neurological disorder unrelated to diabetic peripheral neuropathy or a psychiatric disease, or if they were taking drug treatments other than acetaminophen or insulin.

Treatment Protocol {#jdi12361-sec-0009}
------------------

The protocol for the double‐blind study has been described elsewhere[22](#jdi12361-bib-0022){ref-type="ref"}. Briefly, participants were randomized to receive duloxetine (Cymbalta^®^; Eli Lilly Japan K.K, Kobe, Japan, and Shionogi & Co. Ltd, Osaka, Japan) or placebo for 12 weeks. In the long‐term study described here, all participants, regardless of treatment during the double‐blind study, were re‐randomized (1:1) to receive duloxetine 40 mg/day or 60 mg/day. Participants were re‐randomized using a stochastic minimization method taking into account the following factors from the double‐blind study: (i) treatment group; (ii) improvement in Brief Pain Inventory (BPI) severity -- average pain score of \>30% or \<30%; and (iii) investigational site.

The present long‐term study included tapering and treatment periods. Participants took duloxetine 20 mg/day during week 1, 40 mg/day during week 2, 40 or 60 mg/day (depending on treatment group) during weeks 3--50, 40 mg/day during week 51 and 20 mg/day during week 52.

Study visits occurred biweekly during the first 4 weeks and every 4 weeks thereafter. Study visits also occurred at weeks 50 and 51 for the 60 mg/day and 40 mg/day treatment groups, respectively, before the final study visit at week 52 (or at discontinuation). Baseline was defined as the measurement obtained immediately before the start of duloxetine or placebo treatment in the double‐blind study. The study end‐point was the last available observation. The maximum duration of treatment with duloxetine was 52 weeks for participants who had received a placebo during the double‐blind study and 65 weeks for participants who had received duloxetine during both studies.

Efficacy Measures {#jdi12361-sec-0010}
-----------------

The efficacy outcomes in this long‐term study were pain and quality of life. Pain was measured by the participant‐rated BPI severity (from 0 \[no pain\] to 10 \[pain as bad as you can imagine\]) and interference (from 0 \[does not interfere\] to 10 \[completely interferes\]) scales[22](#jdi12361-bib-0022){ref-type="ref"}, [27](#jdi12361-bib-0027){ref-type="ref"}. The BPI severity subscores included average pain, worst pain, least pain and current pain. The BPI interference scale measured patient functionalities, including general activity, mood, walking, work, relations with others, sleep, enjoyment of life and the mean of these seven items. Quality of life was also evaluated by the Patient\'s Global Impression of Improvement (PGI‐I) scale (from 1 \[very much better\] to 7 \[very much worse\])[28](#jdi12361-bib-0028){ref-type="ref"}.

Safety/Tolerability Measures {#jdi12361-sec-0011}
----------------------------

The primary outcome of the long‐term study was the safety/tolerability of duloxetine treatment. This was determined by the frequencies of adverse events (AEs), adverse drug reactions (ADRs) and serious adverse events (SAEs), the rate of discontinuation as a result of AEs, and the severity of AEs (mild, moderate or severe). Events that occurred after the start of the long‐term study or that continued from the double‐blind study were counted as AEs. All AEs were coded and summarized using the Medical Dictionary for Regulatory Activities, Version 11.1. Adverse drug reactions were AEs judged by the investigator to be definitely related, probably related or possibly related to the study drug. The change from the start of the double‐blind study to the end of the long‐term study in metabolic measures (fasting plasma glucose, HbA1c, lipid profile), vital signs (heart rate, systolic blood pressure, diastolic blood pressure), bodyweight and electrocardiogram (defined as normal, borderline or abnormal by the investigator) were also determined. HbA1c was measured according to recommendations from the Japanese Diabetes Society (JDS) and converted to National Glycohemoglobin Standardization Program (NGSP) equivalent values (NGSP %HbA1c = \[1.02 × JDS %HbA1c\] + 0.25%)[29](#jdi12361-bib-0029){ref-type="ref"}.

Statistical Analysis {#jdi12361-sec-0012}
--------------------

Participants were included in the efficacy analysis if they had at least one assessment after the start of the long‐term study, and in the safety analysis if they had taken at least one dose of duloxetine. Efficacy results were also stratified by treatment group in the previous double‐blind study. Values for mean and standard deviation (SD) were calculated for efficacy measures, laboratory measures, and vital signs. Summary statistics were calculated for the change from the start of the double‐blind study (vital signs, metabolic measures, bodyweight) or from the start of the long‐term study (efficacy measures) to the last observation during treatment. Changes in efficacy and laboratory measures were analyzed by Wilcoxon\'s signed‐rank test. Statistical significance was set at *P* \< 0.05. Analyses were carried out using SAS^®^ Version 9.1.3 (SAS Institute Inc, Cary, NC, USA).

Results {#jdi12361-sec-0013}
=======

Participant Disposition and Characteristics {#jdi12361-sec-0014}
-------------------------------------------

In the double‐blind study, 448 potential participants were screened, 339 were randomized and 293 completed the study (Figure [1](#jdi12361-fig-0001){ref-type="fig"})[22](#jdi12361-bib-0022){ref-type="ref"}. A total of 258 participants enrolled in the long‐term study, and were re‐randomized to receive duloxetine 40 mg/day (129 participants) or 60 mg/day (129 participants; Figure [1](#jdi12361-fig-0001){ref-type="fig"}). A total of 99 (77%) and 91 (71%) participants in the 40 mg/day and 60 mg/day groups, respectively, completed the long‐term study. The characteristics of participants in each group in the long‐term study were broadly similar (Table [1](#jdi12361-tbl-0001){ref-type="table-wrap"}).

###### 

Participant demographics and characteristics at baseline

  Characteristic                                          Duloxetine 40 mg/day (*n* = 129)   Duloxetine 60 mg/day (*n* = 129)   Combined Duloxetine (*n* = 258)
  ------------------------------------------------------- ---------------------------------- ---------------------------------- ---------------------------------
  Mean age (years)                                        60.2 ± 10.5                        60.0 ± 9.6                         60.1 ± 10.0
  Male, *n* (%)                                           89 (69.0)                          107 (82.9)                         196 (76.0)
  Mean weight (kg)                                        63.9 ± 12.1                        65.0 ± 11.6                        64.5 ± 11.8
  Duration of diabetes, *n* (%)                                                                                                 
  \<5 years                                               23 (17.8)                          25 (19.4)                          48 (18.6)
  5--10 years                                             27 (20.9)                          23 (17.8)                          50 (19.4)
  ≥10 years                                               76 (58.9)                          79 (61.2)                          155 (60.1)
  Unknown                                                 3 (2.3)                            2 (1.6)                            5 (1.9)
  Type of diabetes, *n* (%)                                                                                                     
  Type 1                                                  8 (6.2)                            4 (3.1)                            12 (4.7)
  Type 2                                                  121 (93.8)                         125 (96.9)                         246 (95.3)
  Mean duration of DPN (years)                            3.9 ± 3.2                          4.3 ± 3.9                          4.1 ± 3.6
  Mean HbA1c (%)[a](#jdi12361-note-0001){ref-type="fn"}   7.02 ± 0.93                        7.17 ± 0.87                        7.09 ± 0.90
  Mean plasma glucose (mg/dL)                             145.5 ± 57.8                       148.7 ± 61.3                       147.1 ± 59.5

Glycosylated hemoglobin (HbA1c) was measured according to recommendations from the Japanese Diabetes Society and converted to National Glycohemoglobin Standardization Program equivalent values (%HbA1c = \[1.02 × Japanese Diabetes Society %HbA1c\] + 0.25%)[29](#jdi12361-bib-0029){ref-type="ref"}. DPN, diabetic peripheral neuropathy; HbA1c, glycosylated hemoglobin; SD, standard deviation.
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![Participant flow diagram for the double‐blind (DB) and open‐label extension (OLE) studies. †One participant did not receive any study drug and was not assessed at any study visits after the start of the double‐blind study; this participant was excluded from the analysis. ‡One participant discontinued during the taper phase, not the treatment phase. AE, adverse event.](JDI-7-100-g001){#jdi12361-fig-0001}

Efficacy Outcome Measures {#jdi12361-sec-0015}
-------------------------

### Pain {#jdi12361-sec-0016}

The severity of pain, as rated by participants, and the interference caused by that pain, improved during this long‐term study. The BPI severity -- average pain score and all other pain subscores improved significantly (*P* \< 0.0001) from the start of the long‐term study to the end‐point (Figure [2](#jdi12361-fig-0002){ref-type="fig"}; Table S1). The BPI severity -- average pain score decreased from the first week of the study (potentially because some participants had received a placebo in the previous double‐blind study) and continued to decline throughout the study period (Figure [3](#jdi12361-fig-0003){ref-type="fig"}). Changes in the other BPI severity and interference subscores followed a similar time‐course (data not shown). There was no difference between the 40 mg/day and 60 mg/day groups for any BPI measurement of pain severity subscores (Table S1). However, there were greater improvements in most, but not all, measures of BPI severity in participants who had received a placebo in the previous double‐blind study compared with participants who had received duloxetine (Table S1).

![Mean (±standard deviation) change from the start of the long‐term study in Brief Pain Inventory (BPI) severity -- average pain score, Patient\'s Global Impression of Improvement (PGI‐I) score and BPI interference subscores at the end of the long‐term study. Results from the combined duloxetine group (40 mg/day and 60 mg/day, *n* = 257) are presented. All scores decreased significantly from the start of the long‐term study (*P* \< 0.0001 for all scores; Wilcoxon\'s signed‐rank test).](JDI-7-100-g002){#jdi12361-fig-0002}

![Mean (±standard deviation) change in Brief Pain Inventory (BPI) severity -- average pain scores during the long‐term study (50/51 weeks). Results from the combined duloxetine group (40 mg/day and 60 mg/day, *n* = 191--258) are presented.](JDI-7-100-g003){#jdi12361-fig-0003}

### Quality of Life {#jdi12361-sec-0017}

Patient functionality was assessed by BPI interference scores. All BPI interference subscores decreased significantly from the start of the long‐term study, showing improvements in general activity, mood, walking, work, relations with others, sleep and enjoyment of life (Figure [2](#jdi12361-fig-0002){ref-type="fig"}), and continued to decline throughout the study period. All changes in BPI interference scores were similar regardless of treatment group in the double‐blind study (Table S1). The quality of life of participants was mainly measured by PGI‐I (Figure [2](#jdi12361-fig-0002){ref-type="fig"}). The PGI‐I scores significantly (*P* \< 0.0001) decreased from the start of the long‐term study and continued to decline slowly throughout the study. There was no difference between the 40 mg/day and 60 mg/day groups (Table S1). However, there were greater improvements in PGI‐I in participants who had received a placebo in the previous double‐blind study compared with participants who had received duloxetine (Table S1). In addition, the proportion of participants reporting improvements in quality of life increased during the long‐term study (Figure [4](#jdi12361-fig-0004){ref-type="fig"}).

![Proportion of participants at each Patient\'s Global Impression of Improvement (PGI‐I) scale level at the start (*n* = 258) and at the end of the long‐term study (last observation carried forward; *n* = 257). Results from the combined duloxetine group (40 mg/day and 60 mg/day) are presented.](JDI-7-100-g004){#jdi12361-fig-0004}

Safety and Tolerability {#jdi12361-sec-0018}
-----------------------

### Incidence of Adverse Events {#jdi12361-sec-0019}

Most participants (248/258; 96.1%) in the present long‐term study experienced an AE. As in the double‐blind study[22](#jdi12361-bib-0022){ref-type="ref"}, there was no significant difference in the incidence of AEs between the 40 mg/day (126/129; 97.7%) and 60 mg/day (122 of 129; 94.6%) groups. Overall, 54 (20.9%) of 258 participants in the long‐term study discontinued because of an AE (Figure [1](#jdi12361-fig-0001){ref-type="fig"}); one of these participants (60 mg/day group) discontinued during the taper phase (i.e., after finishing the full dose), not during the treatment phase.

In the present long‐term study, there were 12 SAEs in 11 participants in the 40 mg/day group and 34 SAEs in 22 participants in the 60 mg/day group. One participant in the 40 mg/day group died as a result of myocardial ischemia, which was considered unrelated to treatment. There were 11 ADRs in the long‐term study: cerebral infarction, lymphoma and colon cancer in the 40 mg/day group, and generalized edema, cardiac failure, clavicle fracture, thoracic vertebral fracture, spinal compression fracture, lung injury, pneumothorax and gastric cancer in the 60 mg/day group.

### Common Adverse Events {#jdi12361-sec-0020}

In the previous double‐blind study, several AEs occurred in at least 5% of duloxetine‐treated participants, and were at least twice as common in these participants than in placebo‐treated participants. These AEs included the symptoms somnolence, nausea, dizziness, malaise and vomiting, and the laboratory measures increased aspartate aminotransferase and increased white blood cell count[22](#jdi12361-bib-0022){ref-type="ref"}. The incidence of these AEs during the long‐term study (Table [2](#jdi12361-tbl-0002){ref-type="table-wrap"}) was generally similar to the incidence during the double‐blind study[22](#jdi12361-bib-0022){ref-type="ref"}. Other common AEs during the long‐term study, experienced by \>10% of participants, were nasopharyngitis (67 participants; 26.0%), increased HbA1c (60; 23.3%), constipation (34; 13.2%), increased blood glucose (26; 10.1%) and hypoglycemia (26; 10.1%). Only one participant experienced nasopharyngitis that was possibly related to the study drug. The incidence of these AEs during the double‐blind study was similar in both the duloxetine and placebo groups[22](#jdi12361-bib-0022){ref-type="ref"}.

###### 

Incidence of adverse events during the long‐term study

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Preferred term[a](#jdi12361-note-0002){ref-type="fn"}   Duloxetine 40 mg/day (*n* = 129)   Duloxetine 60 mg/day (*n* = 129)   Combined Duloxetine (*n* = 258)
  ------------------------------------------------------- ---------------------------------- ---------------------------------- ---------------------------------
  Symptoms                                                                                                                      

  Somnolence                                              17 (17)\                           18 (18)\                           35 (35)\
                                                          13.2%                              14.0%                              13.6%

  Nausea                                                  14 (16)\                           13 (15)\                           27 (31)\
                                                          10.9%                              10.1%                              10.5%

  Dizziness                                               10 (12)\                           8 (11)\                            18 (23)\
                                                          7.8%                               6.2%                               7.0%

  Malaise                                                 6 (6)\                             5 (5)\                             11 (11)\
                                                          4.7%                               3.9%                               4.3%

  Vomiting                                                9 (11)\                            10 (12)\                           19 (23)\
                                                          7.0%                               7.8%                               7.4%

  Laboratory measures                                                                                                           

  AST increased                                           13 (13)\                           12 (14)\                           25 (27)\
                                                          10.1%                              9.3%                               9.7%

  WBC count increased                                     13 (16)\                           8 (8)\                             21 (24)\
                                                          10.1%                              6.2%                               8.1%
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

According to the Medical Dictionary for Regulatory Activities, Version 11.1. AST, aspartate aminotransferase; WBC, white blood cell.

Data are presented as number of participants, (number of events), and percentage incidence. The table presents events that were experienced by at least 5% of participants in any group during the double‐blind study and were at least twice as common in the combined duloxetine group compared with the placebo group[22](#jdi12361-bib-0022){ref-type="ref"}.
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Most AEs were mild (824/1,914; 43.1%) or moderate (1,055/1,914; 55.1%) in severity and occurred during the first week of treatment (data not shown). The proportion of moderate AEs was somewhat higher in the long‐term study than in the double‐blind study (30.3%)[22](#jdi12361-bib-0022){ref-type="ref"}.

### Vital Signs and Metabolic Measures {#jdi12361-sec-0021}

Vital signs and metabolic measures were assessed from the start of the double‐blind study (baseline) to the end of the long‐term study. There were no clinically significant changes in vital signs, electrocardiogram or bodyweight. There were small, but statistically significant, increases in heart rate (mean change +2.6 b.p.m.; *n* = 242; *P* = 0.0009) and bodyweight (mean change, +1.4 kg; *n* = 241; *P* \< 0.0001). There was a significant increase in HbA1c (mean \[25th percentile, 75th percentile\]) from baseline to end‐point (change +0.45% \[−0.10, 0.92\]; *P* \< 0.0001; *n* = 240). There were also significant increases (mean \[25th percentile, 75th percentile\]) in plasma glucose (+18.4 \[−19.5, 59.0\] mg/dL; *P* \< 0.0001), total cholesterol (+6.4 \[−11.0, 29.0\] mg/dL; *P* = 0.0004), and low‐density lipoprotein cholesterol (+2.1 \[−11.0, 19.0\] mg/dL; *P* = 0.0439; *n* = 240 for all measures). There were no significant changes in high‐density lipoprotein cholesterol or triglycerides.

Discussion {#jdi12361-sec-0022}
==========

This is the first publication of a long‐term (52‐week), randomized, open‐label study carried out in Asia entirely in Japanese patients that evaluated the efficacy and safety of duloxetine in adults with DNP. Long‐term duloxetine treatment was associated with sustained improvements in pain severity, consistent with findings from other studies. For example, 6 months of duloxetine treatment in Caucasian participants with DNP was associated with improvements in BPI severity and the Clinical Global Impression of Severity scores[30](#jdi12361-bib-0030){ref-type="ref"}. Although that study was shorter than the present long‐term study, the improvement in pain was similar. Together, these studies suggest that duloxetine continues to be analgesic over the long term in patients with DNP. Notably, the improvement in pain during our long‐term study was observed regardless of the treatment participants had received during the double‐blind study.

Patients with DNP typically have impaired quality of life, which might be related to the extent and severity of pain[8](#jdi12361-bib-0008){ref-type="ref"}. Participants in the present study reported improved quality of life after long‐term duloxetine treatment, consistent with a 12‐month study in Caucasian patients (in which quality of life was assessed using the 36‐Item Short Form Health Survey and European Quality of Life Instrument‐5D)[23](#jdi12361-bib-0023){ref-type="ref"}. Participants in our study also reported significant improvements in BPI interference, an indirect measure of quality of life. Although the improvements in interference were smaller than those in a 6‐month study[30](#jdi12361-bib-0030){ref-type="ref"}, the present study used lower doses of duloxetine than the shorter study (120 mg/day). We believe the improvements in pain severity and interference experienced by the present study participants contributed to a sustained improvement in quality of life.

Our findings show that duloxetine has an acceptable safety and tolerability profile in Japanese adults with DNP, consistent with findings from long‐term studies in Caucasians[23](#jdi12361-bib-0023){ref-type="ref"}, [24](#jdi12361-bib-0024){ref-type="ref"}. The incidence of AEs was relatively high in both the previous double‐blind study[22](#jdi12361-bib-0022){ref-type="ref"} and the current long‐term study, again consistent with previous studies[18](#jdi12361-bib-0018){ref-type="ref"}, [21](#jdi12361-bib-0021){ref-type="ref"}, [23](#jdi12361-bib-0023){ref-type="ref"}, [24](#jdi12361-bib-0024){ref-type="ref"}, [25](#jdi12361-bib-0025){ref-type="ref"}. However, the rate of discontinuation as a result of an AE in our long‐term study (20.9%) was greater than that among duloxetine‐treated participants in both the 12‐week, double‐blind study (12.2%)[22](#jdi12361-bib-0022){ref-type="ref"} and in other 52‐week studies (5.6%[23](#jdi12361-bib-0023){ref-type="ref"} and 9.3%[24](#jdi12361-bib-0024){ref-type="ref"}). This result suggests that Japanese patients might be more inclined to discontinue as a result of AEs during long‐term duloxetine treatment. However, *post‐hoc* analyses of data from the double‐blind study show that the most common AEs experienced by duloxetine‐treated participants were not persistent. The majority (77.6%) of somnolence, nasopharyngitis and nausea occurrences resolved during the 12‐week study, with mean (±SD) durations of 22.6 ± 27.1 days, 14.7 ± 12.4 days and 10.8 ± 13.2 days, respectively.

As noted, there were no significant or remarkable differences between dose groups in the efficacy or safety of duloxetine in the present long‐term study. Given the similar efficacy between the dose groups, the recommended optimal dose of duloxetine for the treatment of DNP in Japanese patients is considered to be the lower dose of 40 mg/day, at least for 1 year of the dosing period. However, if efficacy is insufficient, the dose might be increased to 60 mg/day with minimal additional risk of adverse events.

In the present study, long‐term duloxetine treatment was associated with changes in metabolic measures, particularly HbA1c and blood glucose, which were greater than those reported for other 52‐week studies of duloxetine[23](#jdi12361-bib-0023){ref-type="ref"}, [24](#jdi12361-bib-0024){ref-type="ref"}. However, the observed increase in HbA1c (0.45%) was below the level at which a clinically meaningful change is likely (0.5%)[31](#jdi12361-bib-0031){ref-type="ref"}. The increase in HbA1c in the long‐term study contrasts with that of the 12‐week, double‐blind study (placebo 0.10%; duloxetine 0.06%)[22](#jdi12361-bib-0022){ref-type="ref"}, suggesting that weekly visits during the double‐blind study might have provided a better opportunity to control participants' diabetes than the monthly visits during the long‐term study. In addition, increased HbA1c is generally associated with long‐term, rather than short‐term, duloxetine treatment[25](#jdi12361-bib-0025){ref-type="ref"}, and could result from progression of diabetes rather than from duloxetine treatment itself. Similarly, the bodyweight changes in our long‐term study were consistent with changes seen in other long‐term duloxetine studies[25](#jdi12361-bib-0025){ref-type="ref"}, [32](#jdi12361-bib-0032){ref-type="ref"}, and, like HbA1c, could be related to diabetes progression rather than duloxetine.

Management of elderly patients with DNP can be complicated by comorbidities and concomitant medications, and the safety and tolerability of some treatments are of particular concern in this population[33](#jdi12361-bib-0033){ref-type="ref"}. To examine the efficacy and safety of duloxetine in the elderly population, we carried out subgroup analyses of data from the double‐blind study. Among elderly participants (aged ≥65 years), the improvement in 24‐h average pain score was significantly greater (*P* \< 0.001) in those treated with duloxetine (*n* = 62) than in those treated with placebo (*n* = 53). Furthermore, the incidence of AEs among elderly participants was similar to that of the overall study population, and no SAEs occurred in this subgroup. Together with the results of other studies[33](#jdi12361-bib-0033){ref-type="ref"}, these results suggest that duloxetine might be an effective and well‐tolerated option for the treatment of elderly patients with DNP, including those from Asia.

The present study is strengthened by the duration of treatment, the involvement of multiple study centers and the exclusive enrolment of Japanese participants with DNP, which allowed evaluation of long‐term duloxetine treatment for the first time in an Asian population. In addition, participants with psychiatric diseases requiring pharmacotherapy were excluded, thereby controlling for the potential confounding effects of treatment with antidepressants. However, the open‐label design and lack of placebo or routine care control group are limitations of the long‐term study. Also, because participants were re‐randomized in the long‐term study, the participants' total exposure to duloxetine varied.

In conclusion, the present findings suggest that duloxetine is an effective long‐term therapy with an acceptable safety and tolerability profile in Japanese patients with DNP. Given that all treatments for DNP are symptomatic only[11](#jdi12361-bib-0011){ref-type="ref"}, duloxetine could be a suitable long‐term treatment option, because it was associated with improvements in both pain severity and the quality of life of patients.
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**Table S1** ¦ Change in efficacy measures from the start of the long‐term study to the end of treatment (overall and stratified by treatment group during the double‐blind study).
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